The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under the Vaccines for Children 2021 program to support pediatric immunization efforts. The contracts hold a potential value of $1.039 billion and were awarded to Glaxosmithkline, LLC for the period of April 1, 2021 through March 31, 2022. The contracts will provide 20 standard pediatric vaccines to the CDC's Immunization Awardees for distribution through the Vaccines for Children program and Section 317(j) of the Public Health Service Act. Estimated quantities range from a minimum of 100 doses to a maximum of 13 million doses per vaccine. Performance will occur across the 50 U.S. states and territories.
The original solicitation sought the vaccines to maintain at least a 12-month shelf life and be manufactured under a current FDA license. Questions were due by January 28, 2021 and offers by February 4, 2021, with award occurring on August 6, 2021. There was no set-aside designation. The vaccines aim to support routine immunization efforts through the CDC's programs, helping to provide pediatric immunizations nationwide.
Generated 3/2/24, 9:08 AM